The gene tests of Kirsten Rat Sarcoma Viral Oncogene (KRAS) (2) and B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) have been used as routine basis for adjuvant therapy, and the detection of wild type or mutant can guide the selection of targeted drugs for initial unresectable CRC. The gene discussed is BRAF; the disease is colorectal carcinoma.